However, one study looked at the budget impact of the third-generation aromatase inhibitors anastrozole and letrozole as alternatives to tamoxifen in postmenopausal women with advanced breast cancer from the perspective of the Italian national health system [35]. Here, CYP19A1 is linked to breast carcinoma.